{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T01:56:26Z","timestamp":1767664586224},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,5,6]],"date-time":"2015-05-06T00:00:00Z","timestamp":1430870400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1007\/s10792-015-0076-4","type":"journal-article","created":{"date-parts":[[2015,5,5]],"date-time":"2015-05-05T10:28:09Z","timestamp":1430821689000},"page":"63-71","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["A comparative study of different concentrations of topical bevacizumab on the recurrence rate of excised primary pterygium: a short-term follow-up study"],"prefix":"10.1007","volume":"36","author":[{"given":"Qader","family":"Motarjemizadeh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naser Samadi","family":"Aidenloo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siamak","family":"Sepehri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,5,6]]},"reference":[{"issue":"9","key":"76_CR1","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1111\/j.1442-9071.2006.01341.x","volume":"34","author":"JJ Farrah","year":"2006","unstructured":"Farrah JJ, Lee GA, Greenrod E, Vieira J (2006) Outcomes of autoconjunctival grafting for primary pterygia when performed by consultant compared with trainee ophthalmologists. Clin Exp Ophthalmol 34(9):857\u2013860. doi: 10.1111\/j.1442-9071.2006.01341.x","journal-title":"Clin Exp Ophthalmol"},{"issue":"2","key":"76_CR2","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/0002-9394(87)90358-8","volume":"98","author":"OD Pinkerton","year":"1984","unstructured":"Pinkerton OD, Hokama Y, Shigemura LA (1984) Immunologic basis for the pathogenesis of pterygium. Am J Ophthalmol 98(2):225\u2013228","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"76_CR3","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1080\/02713680802130354","volume":"33","author":"M Papadia","year":"2008","unstructured":"Papadia M, Barabino S, Valente C, Rolando M (2008) Anatomical and immunological changes of the cornea in patients with pterygium. Curr Eye Res 33(5):429\u2013434. doi: 10.1080\/02713680802130354","journal-title":"Curr Eye Res"},{"issue":"1","key":"76_CR4","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/S1542-0124(12)70103-9","volume":"6","author":"J Chui","year":"2008","unstructured":"Chui J, Di Girolamo N, Wakefield D, Coroneo MT (2008) The pathogenesis of pterygium: current concepts and their therapeutic implications. Ocul Surf 6(1):24\u201343","journal-title":"Ocul Surf"},{"issue":"3","key":"76_CR5","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1080\/08820530902801106","volume":"24","author":"J Mauro","year":"2009","unstructured":"Mauro J, Foster CS (2009) Pterygia: pathogenesis and the role of subconjunctival bevacizumab in treatment. Semin Ophthalmol 24(3):130\u2013134. doi: 10.1080\/08820530902801106","journal-title":"Semin Ophthalmol"},{"issue":"2","key":"76_CR6","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/00006982-200502000-00001","volume":"25","author":"AP Adamis","year":"2005","unstructured":"Adamis AP, Shima DT (2005) The role of vascular endothelial growth factor in ocular health and disease. Retina 25(2):111\u2013118","journal-title":"Retina"},{"issue":"4","key":"76_CR7","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.mehy.2007.01.047","volume":"69","author":"H Hosseini","year":"2007","unstructured":"Hosseini H, Nejabat M, Khalili MR (2007) Bevacizumab (Avastin) as a potential novel adjunct in the management of pterygia. Med Hypotheses 69(4):925\u2013927. doi: 10.1016\/j.mehy.2007.01.047","journal-title":"Med Hypotheses"},{"issue":"1","key":"76_CR8","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1096\/fasebj.13.1.9","volume":"13","author":"G Neufeld","year":"1999","unstructured":"Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z (1999) Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 13(1):9\u201322","journal-title":"FASEB J"},{"issue":"2","key":"76_CR9","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jtos.2012.01.005","volume":"10","author":"W Stevenson","year":"2012","unstructured":"Stevenson W, Cheng SF, Dastjerdi MH, Ferrari G, Dana R (2012) Corneal neovascularization and the utility of topical VEGF inhibition: ranibizumab (Lucentis) vs bevacizumab (Avastin). Ocul Surf 10(2):67\u201383. doi: 10.1016\/j.jtos.2012.01.005","journal-title":"Ocul Surf"},{"issue":"6","key":"76_CR10","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.ajo.2010.01.015","volume":"149","author":"A Galor","year":"2010","unstructured":"Galor A, Yoo SH, Piccoli FV, Schmitt AJ, Chang V, Perez VL (2010) Phase I study of subconjunctival ranibizumab in patients with primary pterygium undergoing pterygium surgery. Am J Ophthalmol 149(6):926\u2013931. doi: 10.1016\/j.ajo.2010.01.015","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"76_CR11","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.bbrc.2005.05.132","volume":"333","author":"N Ferrara","year":"2005","unstructured":"Ferrara N, Hillan KJ, Novotny W (2005) Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 333(2):328\u2013335. doi: 10.1016\/j.bbrc.2005.05.132","journal-title":"Biochem Biophys Res Commun"},{"issue":"23","key":"76_CR12","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","volume":"350","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23):2335\u20132342. doi: 10.1056\/NEJMoa032691","journal-title":"N Engl J Med"},{"issue":"5","key":"76_CR13","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s00347-009-1936-y","volume":"106","author":"S Leippi","year":"2009","unstructured":"Leippi S, Grehn F, Geerling G (2009) Antiangiogenic therapy for pterygium recurrence. Ophthalmologe 106(5):413\u2013419. doi: 10.1007\/s00347-009-1936-y","journal-title":"Ophthalmologe"},{"issue":"6","key":"76_CR14","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1097\/ICO.0b013e3182772d4e","volume":"32","author":"EB Ozgurhan","year":"2013","unstructured":"Ozgurhan EB, Agca A, Kara N, Yuksel K, Demircan A, Demirok A (2013) Topical application of bevacizumab as an adjunct to recurrent pterygium surgery. Cornea 32(6):835\u2013838. doi: 10.1097\/ICO.0b013e3182772d4e","journal-title":"Cornea"},{"issue":"1","key":"76_CR15","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/ICO.0b013e3181822615","volume":"28","author":"PC Wu","year":"2009","unstructured":"Wu PC, Kuo HK, Tai MH, Shin SJ (2009) Topical bevacizumab eyedrops for limbal-conjunctival neovascularization in impending recurrent pterygium. Cornea 28(1):103\u2013104. doi: 10.1097\/ICO.0b013e3181822615","journal-title":"Cornea"},{"issue":"6","key":"76_CR16","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1136\/bjo.82.6.661","volume":"82","author":"JC Sanchez-Thorin","year":"1998","unstructured":"Sanchez-Thorin JC, Rocha G, Yelin JB (1998) Meta-analysis on the recurrence rates after bare sclera resection with and without mitomycin C use and conjunctival autograft placement in surgery for primary pterygium. Br J Ophthalmol 82(6):661\u2013665","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"76_CR17","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3109\/02713680903395273","volume":"35","author":"MR Fallah","year":"2010","unstructured":"Fallah MR, Khosravi K, Hashemian MN, Beheshtnezhad AH, Rajabi MT, Gohari M (2010) Efficacy of topical bevacizumab for inhibiting growth of impending recurrent pterygium. Curr Eye Res 35(1):17\u201322. doi: 10.3109\/02713680903395273","journal-title":"Curr Eye Res"},{"issue":"2","key":"76_CR18","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1136\/bjo.32.2.65","volume":"32","author":"A D\u2019Ombrain","year":"1948","unstructured":"D\u2019Ombrain A (1948) The surgical treatment of pterygium. Br J Ophthalmol 32(2):65\u201371","journal-title":"Br J Ophthalmol"},{"issue":"6","key":"76_CR19","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1097\/ICU.0b013e3282f0ca54","volume":"18","author":"CM Andreoli","year":"2007","unstructured":"Andreoli CM, Miller JW (2007) Anti-vascular endothelial growth factor therapy for ocular neovascular disease. Curr Opin Ophthalmol 18(6):502\u2013508. doi: 10.1097\/ICU.0b013e3282f0ca54","journal-title":"Curr Opin Ophthalmol"},{"issue":"2","key":"76_CR20","doi-asserted-by":"crossref","first-page":"73","DOI":"10.4103\/0974-620X.53036","volume":"2","author":"GJ Manayath","year":"2009","unstructured":"Manayath GJ, Narendran V, Al-Kharousi N, Wali UK (2009) Bevacizumab therapy for macular edema in central retinal vein occlusion: long-term results. Oman J Ophthalmol 2(2):73\u201378. doi: 10.4103\/0974-620X.53036","journal-title":"Oman J Ophthalmol"},{"issue":"2","key":"76_CR21","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1080\/08820530902800330","volume":"24","author":"MS Jardeleza","year":"2009","unstructured":"Jardeleza MS, Miller JW (2009) Review of anti-VEGF therapy in proliferative diabetic retinopathy. Semin Ophthalmol 24(2):87\u201392. doi: 10.1080\/08820530902800330","journal-title":"Semin Ophthalmol"},{"issue":"3","key":"76_CR22","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3109\/08820538.2010.545100","volume":"26","author":"GM El-Mollayess","year":"2011","unstructured":"El-Mollayess GM, Noureddine BN, Bashshur ZF (2011) Bevacizumab and neovascular age related macular degeneration: pathogenesis and treatment. Semin Ophthalmol 26(3):69\u201376. doi: 10.3109\/08820538.2010.545100","journal-title":"Semin Ophthalmol"},{"issue":"10","key":"76_CR23","doi-asserted-by":"crossref","first-page":"579","DOI":"10.4321\/S0365-66912008001000004","volume":"83","author":"PA Martinez-Carpio","year":"2008","unstructured":"Martinez-Carpio PA, Bonafonte-Marquez E, Heredia-Garcia CD, Bonafonte-Royo S (2008) Efficacy and safety of intravitreal injection of bevacizumab in the treatment of neovascular glaucoma: systematic review. Arch Soc Esp Oftalmol 83(10):579\u2013588","journal-title":"Arch Soc Esp Oftalmol"},{"issue":"2","key":"76_CR24","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00417-007-0684-4","volume":"246","author":"F Bock","year":"2008","unstructured":"Bock F, Konig Y, Kruse F, Baier M, Cursiefen C (2008) Bevacizumab (Avastin) eye drops inhibit corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 246(2):281\u2013284. doi: 10.1007\/s00417-007-0684-4","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"11","key":"76_CR25","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1038\/eye.2011.225","volume":"25","author":"JJ Chen","year":"2011","unstructured":"Chen JJ, Ebmeier SE, Sutherland WM, Ghazi NG (2011) Potential penetration of topical ranibizumab (Lucentis) in the rabbit eye. Eye (Lond) 25(11):1504\u20131511. doi: 10.1038\/eye.2011.225","journal-title":"Eye (Lond)"},{"issue":"3","key":"76_CR26","first-page":"512","volume":"7","author":"A Karalezli","year":"2014","unstructured":"Karalezli A, Kucukerdonmez C, Akova YA, Koktekir BE (2014) Does topical bevacizumab prevent postoperative recurrence after pterygium surgery with conjunctival autografting? Int J Ophthalmol 7(3):512\u2013516. doi: 10.3980\/j.issn.2222-3959.2014.03.23","journal-title":"Int J Ophthalmol"},{"issue":"7","key":"76_CR27","doi-asserted-by":"crossref","first-page":"243","DOI":"10.4172\/2155-9570.1000243","volume":"3","author":"A Sudhalkar","year":"2012","unstructured":"Sudhalkar A, Sudhalkar A (2012) Outcomes of post-operative topical bevacizumab in primary pterygium surgery: a case series. J Clin Exp Ophthalmol 3(7):243. doi: 10.4172\/2155-9570.1000243","journal-title":"J Clin Exp Ophthalmol"},{"issue":"267","key":"76_CR28","first-page":"2","volume":"4","author":"H Alhammami","year":"2013","unstructured":"Alhammami H, Farhood Q, Shuber H (2013) Subconjunctival Bevacizumab Injection in Treatment of recurrent Pterygium. J Clin Exp Ophthal 4(267):2. doi: 10.4172\/2155-9570.1000267","journal-title":"J Clin Exp Ophthal"},{"issue":"3","key":"76_CR29","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/ceo.12140","volume":"42","author":"A Nava-Castaneda","year":"2014","unstructured":"Nava-Castaneda A, Olvera-Morales O, Ramos-Castellon C, Garnica-Hayashi L, Garfias Y (2014) Randomized, controlled trial of conjunctival autografting combined with subconjunctival bevacizumab for primary pterygium treatment: 1\u00a0year follow-up. Clin Exp Ophthalmol 42(3):235\u2013241. doi: 10.1111\/ceo.12140","journal-title":"Clin Exp Ophthalmol"},{"issue":"1","key":"76_CR30","first-page":"44","volume":"34","author":"AF Felipe","year":"2009","unstructured":"Felipe AF, Siong RLB, Uy HS (2009) Subconjunctival injection of bevacizumab for treatment of pterygium. Phillip J Ophthalmol 34(1):44\u201350","journal-title":"Phillip J Ophthalmol"},{"issue":"3","key":"76_CR31","first-page":"306","volume":"11","author":"H Khoshniat","year":"2009","unstructured":"Khoshniat H, Jahadi Hosseini H, Nejabat M, Fatehi K, Mosallaei M (2009) Local injection of bevacizumab as an alternative method for management of recurrent pterygium. Iran Red Crescent Med J 11(3):306\u2013311","journal-title":"Iran Red Crescent Med J"},{"issue":"5\u20136","key":"76_CR32","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1159\/000356407","volume":"92","author":"M Waisbourd","year":"2013","unstructured":"Waisbourd M, Levinger E, Varssano D, Moisseiev E, Zayit-Soudri S, Barak A, Loewenstein A, Barequet I (2013) High-dose topical bevacizumab for corneal neovascularization. Pharmacology 92(5\u20136):310\u2013314. doi: 10.1159\/000356407","journal-title":"Pharmacology"},{"key":"76_CR33","first-page":"13","volume":"322","author":"R Razeghinejad","year":"2013","unstructured":"Razeghinejad R, Banifatemi M, Hosseini H (2013) The effect of different doses of subconjunctival bevacizumab on the recurrence rate of excised primary pterygium. Bull Soc Belge Ophtalmol 322:13\u201320","journal-title":"Bull Soc Belge Ophtalmol"},{"issue":"6","key":"76_CR34","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/S0161-6420(97)30197-3","volume":"104","author":"P Prabhasawat","year":"1997","unstructured":"Prabhasawat P, Barton K, Burkett G, Tseng SC (1997) Comparison of conjunctival autografts, amniotic membrane grafts, and primary closure for pterygium excision. Ophthalmology 104(6):974\u2013985","journal-title":"Ophthalmology"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-015-0076-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10792-015-0076-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-015-0076-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,24]],"date-time":"2019-08-24T15:35:30Z","timestamp":1566660930000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10792-015-0076-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,6]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["76"],"URL":"https:\/\/doi.org\/10.1007\/s10792-015-0076-4","relation":{},"ISSN":["0165-5701","1573-2630"],"issn-type":[{"value":"0165-5701","type":"print"},{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,6]]}}}